马来酸曲美布汀联合参苓白术散治疗腹泻型肠易激综合征及对血浆生长抑素、神经肽Y水平影响  

Clinical Observation of Trimebutine Maleate Tablets Combined with Shenlingbaishusan in Treating Diarrhea-predominant Irritable Bowel Syndrome and Study of the Levels of SS, NPY in Serum

作　　者：惠德生[1] 陈随才[1] 张来启[1] 曹娜娅[1] 王芳[1] 

机构地区：[1]榆林市第二医院消化内科,陕西榆林719000

出　　处：《现代生物医学进展》2013年第12期2342-2344,共3页Progress in Modern Biomedicine

摘　　要：目的:观察马来酸曲美布汀联合参苓白术散治疗腹泻型肠易激综合征的临床疗效及对血浆生长抑素(SS)、神经肽Y(NPY)水平的影响。方法:将86例腹泻型肠易激综合征患者随机分为对照组和观察组,每组各43例。对照组采用西药马来酸曲美布汀进行治疗,观察组在此基础上,加用中药复方参苓白术散,治疗周期均为6周,治疗结束后评价疗效,并对治疗前后两组患者血浆SS、NPY水平进行比较。结果:观察组临床总有效率为88.37%,显著高于对照组的60.47%(P<0.05),观察组患者治疗前后血浆SS、NPY水平差异显著,具有统计学意义(P<0.05)。结论:马来酸曲美布汀联合参苓白术散治疗腹泻型肠易激综合征的临床疗效确切,并能调节患者体内异常变化的血浆SS、NPY水平。Objective： To observe the clinical efficacy of trimebutine maleate tablets combined with shenlingbaishusan in treating irritable bowel syndrome with diarrhea （IBS-D）, and to study the levels of somatostatin（SS）, neuropeptide-Y（NPY） in serum. Methods： 86 patients with IBS-D were randomly divided into the observation group （n=43） and control group （n=43）. The patients in the control group were treated with mS-D, and on the basis of this, the observation group were treated with Shenlingbaishusan, the therapeutic cour- se for two groups was 6 weeks. After the treatment, the clinical efficacy was observed and evaluated, and the change of SS and NPY in serum was contracted with the level before the treatment. Results： The total effective rate in the observation group was 88.37%, which was significantly higher than that in the control group （60.47%） （P〈0.05）, the levels ofSS, NPY of the observation group in serum had significantly changes after treatment （P〈0.05）. Conclusion： The treatment of trimebutine maleate tablets combined with shenlingbaishus- an has clinical efficacy in mS-D, and can resume the levels of SS and NPY in serum.

关 键 词：马来酸曲美布汀 参苓白术散 腹泻型肠易激综合征 生长抑素 神经肽Y 

分 类 号：R574[医药卫生—消化系统]